The trttuzumab zuvotolimod (SBT6050) ADC drug with an anti-HER2 mAb and toll-receptor 8 agonist payload is currently undergoing a phase I/II clinical trial (NCT 04460456) to asses anti-cancer activity against solid tumors, including breast cancer, as monotherapy and in combination with PD-1 inhibitors (such as pembrolizumab and cemiplimab) [2,81]. This evidence concerns the gene ERBB2 and breast cancer.